If you have been reading about acetylated peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-02. Numbers and descriptions here follow the published literature rather than marketing material.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Cold agglutinin disease (CAD) is a rare autoimmune disease characterized by the presence of high concentrations of circulating cold sensitive antibodies, usually IgM and autoantibodies that are also active at temperatures below 30 °C (86 °F), directed against red blood cells, causing them to agglutinate and undergo lysis. It is a form of autoimmune hemolytic anemia, specifically one in which antibodies bind red blood cells only at low body temperatures, typically 28–31 °C. When affected people's blood is exposed to cold temperatures (32 °F (0 °C; 273 K) to 50 °F (10 °C; 283 K)), certain proteins that normally attack bacteria (IgM antibodies) attach themselves to red blood cells and bind them together into clumps (agglutination). This eventually causes red blood cells to be prematurely destroyed (hemolysis) leading to anemia and other associated signs and symptoms. Cold agglutinin disease can be primary (unknown cause) or secondary, due to an underlying condition such as an infection, another autoimmune disease, or certain cancers. Treatment depends on many factors including the severity of the condition, the signs and symptoms present in each person, and the underlying cause. Cold agglutinin disease was first described in 1957.
=== The discovery of copper-histidine in human blood and invention of Menkes disease treatment === Sarkar discovered copper-histidine in human blood in 1966 and recognized it as a biological form by which copper, an essential element to sustain life, is transported in blood. In 1976, Sarkar proposed that a baby with Menkes disease receive copper-histidine via subcutaneous injection. This was the world's first Menkes patient to receive copper-histidine therapy. Children with this disease are now living longer and reaching adulthood with copper-histidine treatment. Sarkar did not patent copper-histidine; he intended that it be readily available to Menkes patients at a reasonable cost. The formulation and detailed compounding procedure for the preparation of copper-histidine is freely available by SickKids Pharmacy to physicians and hospital pharmacies around the world upon request. Sarkar also helped make copper-histidine formulation for Menkes disease in other countries, including the NIH Clinical Center, Bethesda, Maryland, USA, India, and Mexico.
Silicosis is the most common occupational lung disease worldwide. Because of work-exposure to silica dust, silicosis is an occupational hazard to construction, railroad, demolition, mining, sandblasting, quarry, tunnelling, ceramics and foundry workers, as well as grinders, stone countertop fabricators, refractory brick workers, tombstone workers, workers in the oil and gas industry, pottery workers, fiberglass manufacturing, glass manufacturing, flintknappers and others. Brief or casual exposure to low levels of crystalline silica dust do not produce clinically significant lung disease. In the United States, it is estimated that between one and two million workers have had occupational exposure to crystalline silica dust and 59,000 of these workers will develop silicosis sometime in the course of their lives. In the US between 1995 and 2004, there was an annual recorded average of roughly 30 silicosis-related deaths. In the UK, the latest data from The Health and Safety Executive show that there are typically between 10 and 20 annual silicosis deaths in recent years, with an average of 12 per year over the last 10 years. There has been a recent rise of cases in Australia, China and the United States associated with the manufacture and installation of engineered stone surfaces in kitchens and bathrooms. Engineered stone has become increasingly common, and it contains a very high proportion of silica, more than natural stone.
== See also == Substituted methoxyphenethylamine 4-Substituted 2,5-dimethoxyphenethylamines (2Cs) 4-Substituted 2,5-dimethoxyamphetamines (DOx) 4-Substituted 2,5-dimethoxy-α-ethylphenethylamines (4Cs) List of miscellaneous 5-HT2A receptor agonists
=== Unknown blood type === Because blood type O negative is compatible with anyone, it is often overused and in short supply. According to the Association for the Advancement of Blood and Biotherapies, the use of this blood should be restricted to persons with O negative blood, as nothing else is compatible with them, and women who might be pregnant and for whom it would be impossible to do blood group testing before giving them emergency treatment. Whenever possible, the AABB recommends that O negative blood be conserved by using blood type testing to identify a less scarce alternative.
Sources: en.wikipedia.org
== Captivity == David Fleay began breeding coastal taipans in 1958, work by Charles Tanner (1911–1996) and him in keeping them in captivity facilitated the production of antivenom. They have proven adaptable to captivity, though they are fast-growing and require food year-round.
==== Main legionary base ==== This shows the castra (base) where the legion spent the longest period during the Principate. Legions often shared the same base with other legions. Detachments of legions were often seconded for lengthy periods to other bases and provinces, as operational needs demanded.
=== Neuropathy === Neuropathy has been a problem in some clinical trials with DCA causing them to be effectively halted, but a 2008 BJC review found that it has not occurred in other DCA trials. The mechanism of DCA induced neuropathy is not well understood. On the one hand in vitro work with nerves has suggested a mechanism for the neuropathic effect of DCA; with DCA showing a dose and exposure dependent demyelination of nerves (stripping of the nerve 'sheath'), which demyelination was partially reversible over time, following washout of DCA. On the other hand, the 2008 review in BJC states "This neurotoxicity resembled the pattern of length-dependent, axonal, sensorimotor polyneuropathy without demyelination." with regard to the 2006 study by Kaufman et al.
Other psychedelic phenethylamines, including the closely related 2C, DOx, and TMA drugs, are inactive as monoamine releasing agents and reuptake inhibitors. However, an exception is trimethoxyamphetamine (TMA), the amphetamine analogue of mescaline, which is a very low-potency serotonin releasing agent (EC50Tooltip half-maximal effective concentration = 16,000 nM). The possible monoamine-releasing effects of mescaline would likely be related to the compound's phenethylamine backbone Mescaline is a relatively low-potency psychedelic, with active doses in the hundreds of milligrams and micromolar affinities for the serotonin 5-HT2A receptor. For comparison, psilocybin is approximately 25-fold more potent (doses in the tens of milligrams) and lysergic acid diethylamide (LSD) is approximately 5,000-fold more potent (doses in the tens to hundreds of micrograms). There have been efforts to develop more potent analogues of mescaline. Difluoromescaline and trifluoromescaline are more potent than mescaline, as is its amphetamine homologue TMA. Escaline and proscaline are also both more potent than mescaline, showing the importance of the 4-position substituent with regard to receptor binding. Mescaline has been uniquely found to robustly produce aggression in rodents, an effect not shared by various other psychedelics. It is unclear why mescaline produces more nausea and vomiting than other psychedelics like LSD and psilocybin in humans.
This single-exon gene was then duplicated in the stem amniote into the three subclasses of interferons, Ia (alpha, beta, delta, epsilon, sigma, nu, omega) Ib (kappa), and Ic (subsequently lost in mammals). The evolution of the Type I IFNs was characterized by extensive gene duplication and non-allelic homologous recombination (NAHR) between the many copies. The NAHR causes further duplication and also homogenizes the blocks by gene conversion. In catarrhine primates (including humans), the region between IFNA14 and IFNA21 remains a recombination hotspot. The evolution of types II and III in amniotes had been a lot less eventful as they generally stayed in the same location from shark to amniotes (between DYRK2 and IL22 for type II, near SYCN, SUPT5H, or TIMM50 for type III), with the exception of the birds and reptiles having duplicated their type II to the so-called IFNLB loci. The loss of introns in type III IFNs happened independently in a few tetrapod groups. Type IV (upsilon) stayed in the same location between the zebrafish and the chicken (between ADARB2 and PFKP) but was lost in humans. The nomenclature of interferons is inconsistent between species, growing in chaoticness as the distance from humans increase. For example, among reptiles, "IFN I" refers to interferon Type Ic and "IFN III" and "IFN IV" are sibling branches of type Ia. Due to the many gene conversion events, using the sequence alone does not always show the correct gene-to-gene correspondence (orthology) and colinearity is needed.
Sources: en.wikipedia.org
==== Adolescents ==== Health Canada has not developed advice for adolescents because of insufficient data. However, they suggest that daily caffeine intake for this age group be no more than 2.5 mg/kg body weight. This is because the maximum adult caffeine dose may not be appropriate for light-weight adolescents or for younger adolescents who are still growing. The daily dose of 2.5 mg/kg body weight would not cause adverse health effects in the majority of adolescent caffeine consumers. This is a conservative suggestion since older and heavier-weight adolescents may be able to consume adult doses of caffeine without experiencing adverse effects.
Several historical varieties of laudanum exist, including Paracelsus' laudanum, Sydenham's Laudanum (also known as tinctura opii crocata), benzoic laudanum (tinctura opii benzoica), and deodorized tincture of opium (the most common contemporary formulation), among others. Depending on the version, additional amounts of the substances and additional active ingredients (e.g. saffron, sugar, eugenol) are added, modifying its effects (e.g., amount of sedation, or antitussive properties). There is probably no single reference that lists all the pharmaceutical variations of laudanum that were created and used in different countries during centuries since it was initially formulated. The reasons are that in addition to official variations described in pharmacopeias, pharmacists and drug manufacturers were free to alter such formulas. The alcohol content of Laudanum probably varied substantially; on the labels of turn-of-the-century bottles of Laudanum, alcoholic content is stated as 48%. In contrast, the current version of Laudanum contains about 18% alcohol. The four variations of laudanum listed here were used in the United States during the late 19th century. The first, from an 1870 publication, is "Best Turkey opium 1 oz., slice, and pour upon it boiling water 1 gill, and work it in a bowl or mortar until it is dissolved; then pour it into the bottle, and with alcohol of 70 percent proof 1⁄2 pt., rinse the dish, adding the alcohol to the preparation, shaking well, and in 24 hours it will be ready for use.
Isavuconazonium, sold under the brand name Cresemba, is a systemic antifungal medication of the triazole class which is used to treat invasive aspergillosis and mucormycosis. It is used as the sulfate. It is taken by mouth or given via injection into a vein. The most common side effects include abnormal liver enzyme tests, nausea, vomiting, difficulty breathing, abdominal pain, diarrhea, injection site reactions, headache, low blood potassium, and skin rash. Isavuconazonium is a prodrug of isavuconazole.
=== Growth Factors === Bioconjugation of TGF-β to iron oxide nanoparticles and its activation through magnetic hyperthermia in-vitro has been reported. This was done by using 1-(3-dimethylaminopropyl)ethylcarbodiimide combined with N-Hydroxysuccinimide to form primary amide bonds with the free primary amines on the growth factor. Carbon nanotubes have been successfully used in conjunction with bioconjugation to link TGF-β followed by an activation with near-infrared light. Typically, these reactions have involved the use of a crosslinker, but some of these add molecular space between the compound of interest and base material and in turn causes higher degrees of non-specific binding and unwanted reactivity.
Georges de Scudéry (1601–1667), novelist, dramatist and poet. Madeleine de Scudéry (1607–1701), writer. Jacques-Henri Bernardin de Saint-Pierre (1737–1814), writer and botanist. Charles Alexandre Lesueur (1778–1846), naturalist, artist and explorer Casimir Delavigne (1793–1843), poet and dramatist. Jacques-François Ancelot (1794–1854), dramatist and litterateur. Frédérick Lemaître (1800–1876), actor and playwright. Eleanor Mary Dennistoun Sellar (1829–1918), Scottish memoirist Léon Gautier (1832–1897), literary historian. Gabriel Monod (1844–1912), historian. Alfred-Louis Brunet-Debaines (1845–c. 1935), artist Juliette Heuzey (1865-1952), writer Louis Bachelier (1870–1946), mathematician Raoul Dufy (1877–1953), painter André Caplet (1878–1925), composer and conductor René Coty (1882–1962), French president (1954–1959) Ivan Đaja (1884–1957), biologist, physiologist, author and philosopher Suzanne Balguerie (1888–1973), French soprano Arthur Honegger (1892–1955), composer, a member of Les Six Thomas Roberts (1893–1976), Roman Catholic archbishop Jean Dubuffet (1901–1985), artist Jean Mallon (1904–1982), palaeographer Raymond Queneau (1903–1976), poet and novelist Jacques Leguerney (1906–1997), composer Bénédicte Pesle (1927–2018), arts patron Jacqueline Danno (1931-2021). actress and singer. Tristan Murail (born 1947), composer Elvire Murail (born 1958), writer for children Laurent Ruquier (born 1963), journalist govy, (1981-2023), artist
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.